Abstract
Patients with nonvalvular atrial fibrillation (AF) and risk factors for stroke need anticoagulation to avoid thromboembolic complications. Vitamin K antagonists (VKAs) are an established pharmacological group the use of which is recommended by guidelines. However, VKAs (like warfarin) have major disadvantages, such as a variable dose-effect relationship, drug and food interactions, the need for regular blood testing and dose titration, and, finally, a substantial risk of bleeding. New oral anticoagulants are intended to replace warfarin, being at least as safe and effective, and lacking some of the disadvantages of VKAs. Clinical data for dabigatran, rivaroxaban, apixaban and edoxaban, and other new drugs, are discussed in this article with special focus on their use in nonvalvular AF.
Keywords: Apixaban, anticoagulation, atrial fibrillation, dabigatran, edoxaban, rivaroxaban, warfarin, ximelagatran.
Current Pharmaceutical Design
Title:Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
Volume: 19 Issue: 21
Author(s): Dariusz Kozlowski, Szymon Budrejko, Grzegorz Raczak, Jacek Rysz and Maciej Banach
Affiliation:
Keywords: Apixaban, anticoagulation, atrial fibrillation, dabigatran, edoxaban, rivaroxaban, warfarin, ximelagatran.
Abstract: Patients with nonvalvular atrial fibrillation (AF) and risk factors for stroke need anticoagulation to avoid thromboembolic complications. Vitamin K antagonists (VKAs) are an established pharmacological group the use of which is recommended by guidelines. However, VKAs (like warfarin) have major disadvantages, such as a variable dose-effect relationship, drug and food interactions, the need for regular blood testing and dose titration, and, finally, a substantial risk of bleeding. New oral anticoagulants are intended to replace warfarin, being at least as safe and effective, and lacking some of the disadvantages of VKAs. Clinical data for dabigatran, rivaroxaban, apixaban and edoxaban, and other new drugs, are discussed in this article with special focus on their use in nonvalvular AF.
Export Options
About this article
Cite this article as:
Kozlowski Dariusz, Budrejko Szymon, Raczak Grzegorz, Rysz Jacek and Banach Maciej, Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/10.2174/1381612811319210007
DOI https://dx.doi.org/10.2174/1381612811319210007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sex Differences and Emerging New Risk Factors for Atherosclerosis and Its Thrombotic Complications
Current Pharmaceutical Design Recent Patents on Rho Signaling Pathway as Therapeutic Target for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Atrial Conduction Disorders
Current Cardiology Reviews Isometric Handgrip Effects on Hypertension
Current Hypertension Reviews ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Cell Sheet Technology for Heart Failure
Current Pharmaceutical Biotechnology Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Pharmacogenetics of Antihypertensive Therapies: Can this be Applied in the Clinic?
Current Pharmacogenomics and Personalized Medicine Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Serenoa Repens, Lycopene and Selenium: A Triple Therapeutic Approach to Manage Benign Prostatic Hyperplasia
Current Medicinal Chemistry Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry The Future of Collateral Artery Research
Current Cardiology Reviews Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design